- US12569455utility2026Therapeutic Agent for Myalgic Encephalomyelitis/chronic Fatigue Syndrome0 cites
- US12527769utility2026Pharmaceutical Composition for Oral Administration of Edaravone and Method of Administering Same0 cites
- US12503445utility2025Compounds and Their Use0 cites
- US12478611utility2025Pharmaceutical Composition for Oral Administration of Edaravone and Method of Administering Same0 cites
- US12404247utility20253, 5-disubstituted Pyridine and 3, 5-disubstituted Pyridazine Derivatives and Pharmaceutical Use of Same0 cites
- US12376781utility2025Brain Wave Analysis Device, Brain Wave Analysis System, and Brain Wave Analysis Program0 cites
- US12338265utility2025Crosslinked Artificial Nucleic Acid ALNA0 cites
- US12310946utility2025Pharmaceutical Composition for Oral Administration of Edaravone and Method of Administering Same0 cites
- US12285409utility2025Edaravone Suspension for Oral Administration0 cites
- US12194025utility2025Pharmaceutical Composition for Oral Administration of Edaravone and Method of Administering Same0 cites
- US12077524utility2024Crystal of Pyrrolidine Compound0 cites
- US11970463utility2024Compounds and Their Use0 cites
- US11957660utility2024Edaravone Suspension for Oral Administration0 cites
- US11958812utility20243, 5-disubstituted Pyridine and 3, 5-disubstituted Pyridazine Derivatives and Pharmaceutical Use of Same0 cites
- US11911366utility2024Pharmaceutical Composition for Oral Administration of Edaravone and Method of Administering Same0 cites
- US11845738utility2023Optically Active Pyrrolidine Compound and Method for Producing Same0 cites
- US11826352utility2023Edaravone Suspension for Oral Administration0 cites
Page 1 of 2Next →